This Oct. 14, 2015 file photo shows the Food and Drug Administration campus in Silver Spring, Md. On Thursday, June 8, 2017, the FDA said it has asked Endo Pharmaceuticals to stop selling its reformulated, extended-release painkiller, Opana ER. (Photo: Andrew Harnik, AP) 
 
 For the first time, the U.S. Food and Drug Administration is asking that a pharmaceutical company withdraw a currently marketed opioid pain medication because of the drug’s potential for abuse. 
 
 The FDA is asking Ireland-based Endo Pharmaceuticals to stop selling reformulated Opana ER, or oxymorphone hydrochloride, because the risks outweigh any benefits of pain control, the FDA said in a statement Thursday. Endo has global headquarters in Dublin but a U.S. base in Malvern, Pa. 
 
 The request comes as the United States finds itself in the middle of what the federal Department of Health and Human Services describes as an “unprecedented opioid epidemic.” More people died in 2014, the most recent year for which data is available, from drug overdoses than any other year on record and more than 60% of those deaths involved an opioid, the federal government says. 
 
 As word of the FDA request circulated, shares of Endo International dipped almost 13% to $11.99 on Thursday. 
 
 The FDA said in its statement that if Endo does not meet its request, it will take steps to withdraw approval of the drug, prescribed when someone needs a long-term pain medication. Endo reformulated Opana ER in a way that the company said would curb the potential for abuse, but an FDA advisory committee voted 18-8 (with one abstention) in mid-March that the benefits of the reformulated version no longer outweigh risks of the drug. 
 
 “The abuse and manipulation of reformulated Opana ER by injection has resulted in a serious disease outbreak,” Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, said in a statement. “This action will protect the public from further potential for misuse and abuse of this product.” 
 
 FDA Commissioner Scott Gottlieb said in a statement: “We are facing an opioid epidemic – a public health crisis – and we must take all necessary steps to reduce the scope of opioid misuse and abuse.” 
 
 Emily Walden of Kentucky lost her 21-year-old son to an Opana overdose in 2012 and traveled to Maryland to give an emotional testimony at the FDA hearing in March. 
 
 “I had a gut feeling it was going to be a big deal,” Walden said of the meeting. 
 
 At that time, her ultimate goal was for the FDA to request Opana’s removal from the market, but her expectations were low. 
 
 “I really did not think that the FDA would follow through,” Walden said Thursday. Now she hopes the FDA will continue to evaluate other opioids and clinical trials. 
 
 She said she had huge concerns about Gottlieb after his appointment, considering his ties to the pharmaceutical industry, but she’s taking this as a sign of good things to come. 
 
 Walden said she has requested meetings with Gottlieb as well as Health and Human Services Secretary Tom Price, but hasn’t had any luck yet. 
 
 “I hope that the commissioner will meet with people like me — parents who have been affected — and get a full picture, not just the pharmaceutical side,” she said. 
 
 Endo said in a statement released Thursday that it is evaluating the FDA request, but also pointed out that during the mid-March meeting, more than half of the advisory committee members said they preferred that Opana ER stay on the market but with added restrictions to prevent abuse. 
 
 Read more: 
 
 “Endo is reviewing the request and is evaluating the full range of potential options as we determine the appropriate path forward,” the company said. 
 
 The company also said that when taken as prescribed, the drug “has a favorable risk-benefit profile.” 
 
 The FDA first approved Opana ER in 2006. In 2012, Endo released a newly formulated version intended to make the drug resistant to abuse by snorting or injecting. The FDA, however, found that “data did not show that the reformulation could be expected to meaningfully reduce abuse." 
 
 Read or Share this story: https://usat.ly/2sZuaGn 

 Breaking News Emails Get breaking news alerts and special reports. The news and stories that matter, delivered weekday mornings. 
 
 / Updated By Maggie Fox 
 
 For the first time ever, the Food and Drug Administration has told a drug company to pull a painkiller off the market because it has such a high potential for abuse. 
 
 The FDA said Thursday that Opana ER, an extended release form of the opioid drug oxymorphone made by the drug company Endo, was being crushed up and injected by people seeking to abuse it. 
 
 The following Schedule 2 narcotics are shown : Morphine Sulfate, OxyContin and Opana on January 18, 2013 in Carmichael, Calif. File Rich Pedroncelli / AP File 
 
 “Today, the U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market,” the FDA said in a statement. 
 
 “After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks. This is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse.” 
 
 The company is pushing back, saying the drug is safe and effective. It's not a gentle request. The FDA says if Endo doesn’t voluntarily pull the drug from the market, it will withdraw approval. 
 
 Related: Florida's Governor Declares Opioid Abuse an Emergency 
 
 “Endo is reviewing the request and is evaluating the full range of potential options as we determine the appropriate path forward,” Endo said in a statement. 
 
 “Despite the FDA's request to withdraw Opana ER from the market, this request does not indicate uncertainty with the product's safety or efficacy when taken as prescribed.” 
 
 “This action will protect the public from further potential for misuse and abuse of this product.” 
 
 Opana is one of many opioid drugs being abused in the opioid epidemic that is sweeping the United States. 
 
 The Centers for Disease Control and Prevention says opioid overdoses have hit record highs, killing more than 40,000 people in 2015 — more than the 32,000 who died in road accidents. 
 
 Related: NIH Launches Push to Fight Opioid Crisis 
 
 "We are facing an opioid epidemic - a public health crisis, and we must take all necessary steps to reduce the scope of opioid misuse and abuse," FDA commissioner Dr. Scott Gottlieb said in a statement. 
 
 Endo, which sold $158 million worth of Opana ER in 2015, had reformulated the pills in 2012 and sought to get them labeled as abuse deterrent. 
 
 The FDA said that reformulation made things worse. 
 
 “The FDA’s decision is based on a review of all available postmarketing data, which demonstrated a significant shift in the route of abuse of Opana ER from nasal to injection following the product’s reformulation,” it said. 
 
 “Injection abuse of reformulated Opana ER has been associated with a serious outbreak of HIV and hepatitis C,” it added. Both viruses spread when people share needles. 
 
 Related: Possibly Fake Percocet Kills Two in Georgia 
 
 Cities and states have started suing makers of opioid drugs, saying that they’ve pushed their drugs on doctors and patients alike, helping drice addiction. Studies show many, if not most, most addicts start out using prescription opioids to treat legitimate pain. 
 
 "Four out of five individuals now suffering from heroin or fentanyl addiction first started down this road by using prescription opioids," Ohio Attorney General Mike DeWine told a hearing in Congress on the opioid epidemic Thursday. 
 
 Endo is one of five companies being sued by Ohio, the second state to sue companies after Mississippi. Everett, Washington sued Purdue Pharma, the maker of the opioid Oxycontin. 
 
 "The abuse and manipulation of reformulated Opana ER by injection has resulted in a serious disease outbreak," said Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research. 
 
 "When we determined that the product had dangerous unintended consequences, we made a decision to request its withdrawal from the market,” Woodcock added in a statement. 
 
 “This action will protect the public from further potential for misuse and abuse of this product.” 

 FILE - This Oct. 14, 2015 file photo shows the Food and Drug Administration campus in Silver Spring, Md. On Thursday, June 8, 2017, the FDA said it has asked Endo Pharmaceuticals to stop selling its reformulated,... (Associated Press) 
 
 FILE - This Oct. 14, 2015 file photo shows the Food and Drug Administration campus in Silver Spring, Md. On Thursday, June 8, 2017, the FDA said it has asked Endo Pharmaceuticals to stop selling its reformulated,... (Associated Press) 
 
 TRENTON, N.J. (AP) — U.S. regulators want a narcotic painkiller involved in the opioid epidemic off the market amid data showing people continue to abuse it. 
 
 The Food and Drug Administration said Thursday it has asked Endo Pharmaceuticals to stop selling its reformulated, extended-release painkiller, Opana ER, after concluding the drugs's risks outweigh its benefits. 
 
 It's the first time the FDA has asked a drugmaker to remove an opioid painkiller from the market. The agency said it has seen a "significant shift" from people crushing and snorting Opana ER to get high to injecting it. 
 
 Endo said in a statement it's "reviewing the request and is evaluating the full range of potential options." 
 
 Wall Street responded quickly with a sell-off, and Endo shares plunged 13.4 percent to $11.93 in trading after U.S. markets closed. 
 
 The FDA move comes after advisers, reviewing the safety of Opana ER at a March hearing, voted 18-8 against keeping it on the market. 
 
 Besides contributing to overdoses, abuse of Opana ER was blamed for a 2015 outbreak of HIV and hepatitis C in southern Indiana linked to sharing needles, according to the FDA. 
 
 "We are facing an opioid epidemic - a public health crisis, and we must take all necessary steps to reduce the scope of opioid misuse and abuse," FDA Commissioner Dr. Scott Gottlieb said in a statement. "We will continue to take regulatory steps when we see situations where an opioid product's risks outweigh its benefits." 
 
 About 2 million Americans are addicted to prescription opioids, and 91 die every day from overdosing on a painkiller or much-cheaper heroin. 
 
 Endo first got U.S. approval for its extended-release opioid, Opana ER, in 2006. It reformulated that drug in 2012 and claimed the changes made it harder to manipulate physically or chemically to abuse it. Endo tried to persuade FDA officials that the new formulation was abuse-resistant, which likely would have given the product a marketing advantage in the crowded, lucrative category of opioid painkillers. 
 
 The FDA didn't agree, refusing to let Endo market the new formulation as abuse deterrent when it granted approval for sales several years ago. 
 
 If Endo doesn't comply with the FDA's request to stop selling Opana ER, the agency can hold a hearing and start a formal process for rescinding its approval. 
 
 According to the FDA, there are no generic versions of the reformulated Opana ER on the market. However, generic versions of both the original Opana ER and the original immediate-release version, called oxymorphone ER, are on sale. 
 
 Those generic products might also face action by the FDA, which said it is "assessing the latest available data on abuse patterns." 
 
 Endo Pharmaceuticals makes generic pills and specialty drugs, which generally are expensive medicines for complex disorders. It's part of Endo International plc, which is based in Dublin, Ireland, and has U.S. headquarters in the Philadelphia suburb of Malvern. 
 
 Endo had about $4 billion in revenue last year, only $159 million of that from Opana. 
 
 ___ 
 
 Follow Linda A. Johnson on Twitter: @LindaJ_onPharma
– The FDA is asking an Irish pharmaceutical company to take one of its pain medications off the market because of its contributions to America's opioid epidemic, USA Today reports. The FDA says it's the first time it's ever asked a company to withdraw an opioid pain medication "due to the public health consequences of abuse," according to NBC News. Endo International's Opana ER was first approved by the FDA in 2006; a reformulated version of Opana ER, meant to lessen the potential for abuse, was released in 2012. But the FDA, in an 18-8 vote, ruled the benefits of the reformulated version are outweighed by the risk of abuse, largely from crushing and injecting the drug. Endo argues its drug is both safe and effective. Endo states it's evaluating the FDA's request. The company sold $158 million worth of Opana ER in 2015. The FDA states that if Endo doesn't voluntarily take Opana ER off the market, it will begin the process of withdrawing its approval of the drug. “I really did not think that the FDA would follow through,” says a woman who lost her 21-year-old son to an Opana overdose and later testified before the FDA. In addition to being linked to the growing opioid crisis in the US, Opana ER was blamed for an outbreak of HIV and hepatitis C in 2015 in Indiana, the AP reports. Approximately 2 million Americans are addicted to prescription opioids. According to the CDC, opioid overdoses killed more than 40,000 Americans in 2015—a record high.